Vantia Therapeutics' Pipeline - VA106483 (nocturia)

VA106483 is a novel small molecule drug candidate, discovered by Vantia Therapeutics, which is in Phase II trials to treat nocturia, a common condition that causes sufferers to wake frequently during the night in order to urinate, thus interrupting sleep.

VA106483 acts directly in the collecting ducts of the kidney by binding to vasopressin (V₂) receptors. Clinical data indicate that VA106483 is generally well tolerated and is an effective anti-diuretic that increases urine concentration and reduces urine output.

Vantia Therapeutics' initial indication for VA106483 is nocturia. A Phase II clinical programme has been designed and trials are underway, with initial results expected mid-2009.

Market Opportunity

Nocturia is commonly associated with benign prostatic hypertrophy (BPH) where it is estimated to affect up to 70% of BPH patients. With estimates putting the number of BPH/nocturia sufferers at 55 million in the seven largest markets world wide, and only 10% of these believed to be receiving any kind of treatment, it is a clear area of unmet medical need and estimated to be worth in excess of $500m per annum. This figure excludes nocturia resulting from other causes such as overactive bladder, which represent further significant opportunities.